title: Is sequential low-dose immunotherapy the preferred treatment in cadaveric renal transplantation?
authors.affiliation: Department of Surgery, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298.
authors.forename: M P
authors.initials: MP
authors.lastname: Posner
authors.forename: G
authors.initials: G
authors.lastname: Mendez-Picon
authors.forename: A
authors.initials: A
authors.lastname: King
authors.forename: K P
authors.initials: KP
authors.lastname: Nelson
authors.forename: H G
authors.initials: HG
authors.lastname: Spicer
authors.forename: H M
authors.initials: HM
authors.lastname: Lee
mesh_terms: D000961:Antilymphocyte Serum / Q000008:administration & dosage* / Q000627:therapeutic use; D001379:Azathioprine / Q000008:administration & dosage* / Q000627:therapeutic use; D002102:Cadaver; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D003524:Cyclosporins / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000187:drug effects; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D016030:Kidney Transplantation; D011241:Prednisone / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D000961:Antilymphocyte Serum; D003524:Cyclosporins; D003404:Creatinine; D001379:Azathioprine; D011241:Prednisone